High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
作者信息
Gambella Manuela, Rocci Alberto, Passera Roberto, Gay Francesca, Omedè Paola, Crippa Claudia, Corradini Paolo, Romano Alessandra, Rossi Davide, Ladetto Marco, Boccadoro Mario, Palumbo Antonio
出版信息
Haematologica. 2014 Feb;99(2):e14-6. doi: 10.3324/haematol.2013.090142.
Abstract
摘要
相似文献
1
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
Haematologica. 2014 Feb;99(2):e14-6. doi: 10.3324/haematol.2013.090142.
2
Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
Blood. 2007 Apr 15;109(8):3610-1. doi: 10.1182/blood-2006-09-048769.
3
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Blood. 2008 Jan 15;111(2):968-9. doi: 10.1182/blood-2007-10-119321.
4
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.
5
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Int J Oncol. 2012 Sep;41(3):876-84. doi: 10.3892/ijo.2012.1545. Epub 2012 Jul 4.
6
Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
Biochem Biophys Res Commun. 2012 Apr 13;420(3):644-50. doi: 10.1016/j.bbrc.2012.03.056. Epub 2012 Mar 17.
7
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.
8
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood. 2007 Apr 15;109(8):3177-88. doi: 10.1182/blood-2006-09-044974. Epub 2006 Dec 21.
9
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Haematologica. 2012 Jan;97(1):64-72. doi: 10.3324/haematol.2011.043331. Epub 2011 Oct 11.
10
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Clin Cancer Res. 2013 Mar 15;19(6):1534-46. doi: 10.1158/1078-0432.CCR-12-1429. Epub 2013 Jan 28.
引用本文的文献
1
The role of the unfolded protein response pathway in bone homeostasis and potential therapeutic target in cancer-associated bone disease.
Bone Res. 2025 Aug 28;13(1):76. doi: 10.1038/s41413-025-00457-6.
2
Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma.
Clin Exp Med. 2025 May 26;25(1):176. doi: 10.1007/s10238-025-01713-z.
3
Prognostic implications of MUC1 and XBP1 concordant expression in multiple myeloma: A retrospective study.
PLoS One. 2025 Apr 3;20(4):e0320934. doi: 10.1371/journal.pone.0320934. eCollection 2025.
4
Correlation Between Low Cytoplasmic Expression of XBP1 and the Likelihood of Surviving Hepatocellular Carcinoma.
In Vivo. 2024 May-Jun;38(3):1316-1324. doi: 10.21873/invivo.13571.
5
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Nat Cancer. 2023 Dec;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1. Epub 2023 Nov 9.
6
Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma.
Int J Mol Sci. 2023 Mar 23;24(7):6019. doi: 10.3390/ijms24076019.
7
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.
Int J Mol Sci. 2022 Dec 30;24(1):644. doi: 10.3390/ijms24010644.
8
Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Am J Cancer Res. 2022 Jul 15;12(7):3280-3293. eCollection 2022.
9
IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies.
Cancers (Basel). 2022 May 20;14(10):2526. doi: 10.3390/cancers14102526.
10
The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
Cells. 2021 Dec 8;10(12):3464. doi: 10.3390/cells10123464.
本文引用的文献
1
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Haematologica. 2012 Jan;97(1):64-72. doi: 10.3324/haematol.2011.043331. Epub 2011 Oct 11.
2
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Br J Haematol. 2011 Aug;154(3):325-36. doi: 10.1111/j.1365-2141.2011.08689.x. Epub 2011 Jun 24.
3
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.
4
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
Blood. 2010 Jul 15;116(2):250-3. doi: 10.1182/blood-2010-01-263236. Epub 2010 Apr 26.
5
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4.
6
Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma.
Leukemia. 2008 Feb;22(2):441-5. doi: 10.1038/sj.leu.2404895. Epub 2007 Aug 9.
7
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Cancer Res. 2007 Feb 15;67(4):1783-92. doi: 10.1158/0008-5472.CAN-06-2258.
8
International uniform response criteria for multiple myeloma.
Leukemia. 2006 Sep;20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20.
9
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.
Nat Immunol. 2006 Jul;7(7):773-82. doi: 10.1038/ni1357. Epub 2006 Jun 11.
10
Plasma cell differentiation requires the transcription factor XBP-1.
Nature. 2001 Jul 19;412(6844):300-7. doi: 10.1038/35085509.
Zotero 插件